anti-CEACAM6 PEGylated ScFv (University of Arizona)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CEACAM6 PEGylated ScFv (University of Arizona)

Drug Alias Nameanti-CEACAM6 ScFv

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyDiagnostic agent (In vivo)

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 agonists

TargetsCarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesThe University Of Arizona

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe University Of Arizona

Active IndicationsN/A

Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A